cobas BRAF V600 Mutation Test
Roche Molecular Systems, Inc. · Decision date Mar 17, 2026
What did the FDA decide?
FDA records P110020/S044 as a supplement to PMA P110020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 17, 2026.
FDA approval order statement
to revise QC methods for supplied materials
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Mar 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P110020/S044
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- Decision code
- OK30
- Decision date
- Mar 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110020 · Original PMA
COBAS 4800 BRAF V600 MUTATION TEST
P110020/S043 · Related supplement
cobsa BRAF V600 Mutation Test
P110020/S044 received
Application receipt date recorded by FDA.
P110020/S044 · FDA decision
30-Day Notice
P110020/S045 · Related supplement
cobas BRAF V600 Mutation Test
P110020/S046 · Related supplement
Roche cobas BRAF V600 Mutation Test
Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Roche Molecular Systems, Inc. | PMA approval | Aug 17, 2011 | FDA | |
cobsa BRAF V600 Mutation TestP110020/S043 | Roche Molecular Systems, Inc. | PMA supplement | Dec 31, 2025 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P110020/S044
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





